1/35
Looks like no tags are added yet.
Dementia
A chronic, progressive syndrome characterized by a irreversible decline in cognitive function, impairment of memory, and loss of brain function that interferes with daily living and occupational capabilities.
Alzheimer’s Disease (AD)
The most common form of dementia. Changes begin decades before clinical symptoms appear; significant, irreversible neuronal damage is present at diagnosis.
Amyloid Beta Plaques
Abnormal protein clumps accumulating in extracellular spaces between neurons.
Neurofibrillary Tau Tangles
Twisted protein fibers forming inside damaged neurons.
Neuroinflammation
A chronic inflammatory response triggered by plaques and tangles that accelerates cell damage.
Vicious Cycle & Cerebral Atrophy
Ongoing neuroinflammation, plaque, and tangle accumulation cause mass neuron death, leading to severe cerebral atrophy, loss of synaptic connections, physical decline, and death.
Non-Modifiable Risk Factors:
Age: Single greatest risk factor (risk rises significantly after age 65).
Genetics & Family History: Apolipoprotein E (APOE-ε4) gene increases risk up to 4x; first-degree relative history.
Sex: Females > Males (partially due to longer average lifespan).
Modifiable / Lifestyle Risk Factors- Cardiovascular & Metabolic
Mid-life hypertension, type 2 diabetes, obesity, hyperlipidemia, stroke history.
Modifiable / Lifestyle Risk Factors- Lifestyle
Physical inactivity, smoking, alcohol abuse, poor diet (high saturated fat/sugar/salt), untreated obstructive sleep apnea.
Modifiable / Lifestyle Risk Factors- Sensory & Social
Hearing loss, vision loss, social isolation, low lifelong cognitive engagement.
Modifiable / Lifestyle Risk Factors- Mental Health & Safety
Depression in mid/late life, repeated traumatic brain injury (TBI)/head trauma.
Modifiable / Lifestyle Risk Factors- Environmental
High exposure to fine particle air pollution near heavy traffic corridors.
Stage 1: Mild (Early Stage) key manifestations
Mild short-term memory loss, misplacing household objects, difficulty finding words/terms in conversation, subtle changes in judgment, trouble planning or performing familiar tasks independently.
Stage 2: Moderate (Middle Stage) key manifestations
Noticeable mood/personality shifts (agitation, paranoia), confusion regarding time or place, difficulty speaking, reading, or writing, inability to perform complex tasks or managing personal finances independently.
Stage 3: Severe (Late Stage) key manifestations
Complete loss of ability to perform Activities of Daily Living (ADLs), loss of swallowing/chewing reflex (high aspiration risk), incontinence (bowel and bladder), loss of recognition of family members, immobility.
Diagnostics
is achieved by ruling out reversible causes (e.g., Delirium, Depression, Thyroid dysfunction, Vitamin B12 deficiency) and confirming cognitive impairment.
Clinical Assessment & History
History of onset, duration, and progression of behavioral changes, functional assessment, and standardized tool screening (e.g., MMSE).
CT / MRI
Evaluates structural brain shrinkage (atrophy) or rules out mass lesions and strokes.
PET Scan
Visualizes abnormal accumulation of amyloid plaques or tau tangles in brain tissue.
Lumbar Puncture (LP)
Measures elevated CSF amyloid-beta and tau protein levels.
Laboratory Testing
CBC, CMP, TSH, Vitamin B12, Urinalysis, and blood biomarker tests (e.g., elevated p-tau217 levels).
Genetic testing (APOE).
Safety First
Keep bed in lowest position, place fall-risk alarms, ensure well-lit environment, remove scatter rugs, and secure doors if wandering occurs.
Environment & Routine
Provide a structured, predictable routine with minimal changes; assign consistent caregivers to decrease anxiety and confusion.
Validation Therapy vs. Reorientation- Mild Stage
Reorient frequently to time, place, and person using clocks, calendars, and signs.
Validation Therapy vs. Reorientation- Moderate to Severe Stage
Use Validation Therapy—validate feelings rather than arguing or forcing reality when the patient is agitated or delusional.
Communication Strategies
Speak calmly using short, simple, direct sentences and clear statements.
Give one direct instruction at a time and allow extra response time.
Avoid complex choices, direct confrontations, or arguing.
Supportive Care
Assist with ADLs while promoting maximum independence for safe activities.
Screen for caregiver burden/burnout; refer to community resources (e.g., Alzheimer’s Association, National Institute on Aging, respite care, support groups).
Cholinesterase Inhibitors
Generic (Brand): Donepezil, Rivastigmine
Cholinesterase Inhibitors key mechanism
Prevents breakdown of acetylcholine to slow cognitive decline.
Cholinesterase Inhibitors- Nursing Considerations & Client Education
Take at bedtime (Donepezil) to reduce fall risk from bradycardia/syncope. Side effects include GI distress (nausea, vomiting, diarrhea), bradycardia, and dizziness. Monitor heart rate and weight regularly.
NMDA Receptor Antagonists
Generic (Brand): Memantine
NMDA Receptor Antagonists- Key Mechanism
Regulates glutamate activity to slow cell damage in moderate-to-severe AD.
NMDA Receptor Antagonists- Nursing Considerations & Client Education
Can be given alongside cholinesterase inhibitors. Monitor for dizziness, confusion, and headache. Administer cautiously in renal impairment.
SSRIs
Generic (Brand): Sertraline
SSRIs- Key Mechanism
Manages secondary depressive symptoms and mood disturbances
SSRIs- Nursing Considerations & Client Education
Monitor for serotonin syndrome and increased fall risk. Instruct family that therapeutic effect takes 2–4 weeks.